Showing results (61-70 of 164) with videos related to
Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2012
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumorsAung Naing, Patricia LoRusso, Siqing Fu, et al.Plos One|November 17, 2018
Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancerZ Ping Lin, Yong-Lian Zhu, Ying-Chun Lo, et al.Cancer Chemotherapy and Pharmacology|August 11, 2016
Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumorsDing Wang, Fadi Braiteh, James J Lee, et al.Cancer Chemotherapy and Pharmacology|September 24, 2013
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528Shirish M Gadgeel, Danika L Lew, Timothy W Synold, et al.Investigational New Drugs|June 25, 2008
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumorsPatricia Lorusso, Elisabeth I Heath, Jesse McGreivy, et al.Cancer|May 12, 2005
A phase II study of bortezomib in the treatment of metastatic malignant melanomaSvetomir N Markovic, Susan M Geyer, Fitzroy Dawkins, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumorsCristiana Sessa, Patricia Lorusso, Anthony Tolcher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibitionJoan Albanell, Federico Rojo, Steve Averbuch, et al.Cancer Chemotherapy and Pharmacology|October 1, 2015
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumorsAnthony W Tolcher, Patricia LoRusso, Jennifer Arzt, et al.Journal of Clinical Pharmacology|November 5, 2002
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastasesTianling Chen, James Berenson, Robert Vescio, et al.Pageof 17